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Although we have had efficacious 
medications for both schizophre-
nia and bipolar disorder for over 
half a century, there remains a clear 
need for more effective and better- 
tolerated treatments for both 
conditions. Current antipsychotics 
often have troubling side-effect 
profiles particularly with respect 
to weight gain and cardiometa-
bolic parameters. These draw-
backs also extend to treatment 
of mania and there are very few 
evidence-based treatments for the 
depressed phases of bipolar dis-
order. The introduction of a novel 
treatment with a potentially bet-
ter risk-to-benefit profile is there-
fore welcome.
Lurasidone is a novel second-generation antipsychotic.1 Like other newer antipsy-
chotics, it is an antagonist at 
dopamine D2 and 5HT2A receptors 
but it has less affinity for alpha1 
receptors than other second-gen-
eration antipsychotics and negli-
gible affinity for histamine H1 and 
muscarinic receptors. Unusually, 
it also has high affinity for 5HT1A 
receptors, which are believed to 
be important for anxiolytic and 
antidepressant activity and 5HT7 
receptors, which appear to have 
a role in learning and memory. 
 These pharmacological char-
acteristics suggest that lurasidone, 
in addition to its efficacy as an 
antipsychotic, has the potential 
to improve cognitive deficits and 
depressive symptoms associated 
with schizophrenia and is likely 
to be associated with a low risk of 
weight gain and metabolic dysfunc-
tion.
CLINICAL TRIALS EFFICACY
Schizophrenia
The Program to Evaluate the 
Antipsychotic Response to Lurasi-
done (PEARL) comprised three 
phase 3 randomised trials of simi-
lar design.2–6 Patients with acute 
exacerbation of schizophrenia 
and Positive and Negative Syn-
drome Scale (PANSS) total score 
≥80 were randomised to treatment 
with lurasidone 40, 80 or 120mg 
daily or placebo (PEARL1). Non-
comparative active controls were 
included in PEARL2 (olanzapine 
15mg daily)3 and PEARL3 (mod-
ified-release quetiapine 600mg 
daily).5 All consisted of a fixed-dose 
double-blind phase of six weeks fol-
lowed by a flexible-dose extension 
phase. The primary end-point in 
each study was the change from 
baseline in the PANSS total score; 
secondary end-points included the 
PANSS positive and negative scores 
and the Clinical Global Impres-
sion-Severity (CGI-S) score.
 In PEARL1 (n=500), lurasidone 
80mg daily significantly improved 
total PANSS and CGI-S scores 
compared with placebo at six 
weeks, though neither the lower or 
higher dose did so.2 Positive symp-
toms were significantly improved 
at doses of 80 and 120mg daily but 
not 40mg daily, and there was no 
difference between lurasidone and 
placebo in change in PANSS nega-
tive symptom score or in symptoms 
Lurasidone: new development 
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Figure 1. Change from baseline in PANSS total score for lurasidone 40 or 120mg vs placebo with  
olanzapine as active control (PEARL2)3
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of depression. The results of the 
PEARL1 extension study are not 
yet available.
 In PEARL2 (n=478), lurasidone 
40 or 120mg daily both signifi-
cantly improved PANSS total score, 
PANSS positive and negative scores 
and CGI-S score compared with 
placebo after six weeks (see Figure 
1). Significant separation was evi-
dent at the end of the first week.3 
Olanzapine 15mg, as an active con-
trol, was also superior to placebo.
 In PEARL3 (n=488), patients 
were randomised to treatment 
with lurasidone 80 or 160mg daily, 
placebo or modified-release (m/r) 
quetiapine 600mg daily.5 Both 
doses of lurasidone significantly 
improved PANSS total, positive and 
negative scores and CGI-S score by 
six weeks compared with placebo, 
with similar efficacy as quetiapine 
(see Figure 2). 
 Lurasidone also significantly 
improved depression scores 
(Montgomery-Asberg Depression 
Rating Scale, MADRS), negative 
symptoms (Negative Symptom 
Assessment Scale) and somnolence 
(Epworth scale) compared with 
placebo.
 Patients who responded to 
treatment with lurasidone or 
quetiapine (≥20% reduction in 
PANSS total score and CGI-S ≤4 
at six weeks) were eligible to enter 
a noninferiority trial to compare 
their efficacy in preventing relapse 
(n=292).6 The initial blinding was 
maintained. The probability of 
relapse over 12 months was 24 per 
cent with lurasidone and 34 per 
cent with quetiapine, meeting the 
criterion for noninferiority. Lur-
asidone was also associated with a 
lower 12-month relapse rate (24 vs 
34% with quetiapine), a lower rate 
of hospital admission (9.8 vs 23%) 
and a higher rate of remission (62 
vs 46%).
 A recent meta-analysis compre-
hensively compared the efficacy of 
lurasidone to placebo and other 
antipsychotics commonly used to 
treat schizophrenia.7 Lurasidone 
treatment produced a relatively 
small but significant improvement 
in symptoms of schizophrenia 
compared to placebo (standard 
mean difference 0.33). Lurasi-
done was, however, significantly 
less effective at treating symptoms 
of schizophrenia than clozapine, 
amisulpride, olanzapine, risperi-
done and paliperidone (Invega) 
and had similar efficacy pro-
files to haloperidol, quetiapine, 
chlorpromazine and asenapine 
(Sycrest). 
Symptoms of depression in patients 
with schizophrenia
A post-hoc analysis of four six-week 
double-blind placebo-controlled 
trials that had included an assess-
ment of depressive symptoms 
(n=1341) found that lurasidone 
40–160mg daily significantly 
improved MADRS scores overall 
and in each subgroup defined 
by baseline symptom severity.8 
However, further analysis by dose 
showed that only 80 and 160mg 
daily were statistically superior to 
placebo. 
 In patients with clinically sig-
nificant depression at baseline 
(MADRS ≥16), the proportions of 
patients in remission at six weeks 
were 27% with placebo and 39 and 
48% with lurasidone 80 and 160mg 
daily.
Cognitive function in patients with 
schizophrenia
Cognitive function was assessed 
in the PEARL3 trial.9 There were 
no significant differences between 
lurasidone and placebo (or que-
tiapine vs placebo) at six weeks 
but after 32 weeks lurasidone 
improved cognitive function sig-
nificantly more than quetiapine. 
This was independent of PANSS 
positive, PANSS negative or over-
all symptom reductions at weeks 6 
and 32.
Bipolar I depression 
Lurasidone has been evaluated in 
the treatment of bipolar I depres-
sion (baseline MADRS score ≥20) 
in two double-blind placebo-con-
trolled trials. 
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Figure 2. Change from baseline in PANSS total score for lurasidone 80 or 160mg vs placebo with m/r 
quetiapine as active control (PEARL3)5
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 In PREVAIL1 (n=346), lurasi-
done 20–120mg daily was added 
to treatment with either lithium 
or valproate.10 After six weeks, 
lurasidone improved depressive 
symptoms significantly more than 
placebo (MADRS score: -17.1 vs 
-13.5 with placebo, p<0.01, effect 
size 0.30; CGI-bipolar depression 
severity rating: -2.0 vs -1.5 with 
placebo, p<0.01 effect size 0.36), 
with secondary end-points dem-
onstrating a reduction in disabil-
ity (Sheehan Disability Scale total 
score -9.5 vs -7.0 with placebo; 
p≤0.01). 
 PREVAIL2 randomised 505 
patients to monotherapy with 
lurasidone 20–60mg daily or 
80–120mg daily or placebo.11 After 
six weeks, lurasidone improved 
depressive symptoms (MADRS 
score -15.4 for each dose vs -10.7 
with placebo, p<0.001; CGI-bipolar 
depression severity rating -1.8 and 
–1.7 vs -1.1 with placebo, p<0.001), 
disability and quality-of-life scores 
compared with placebo, with no 
difference in outcomes between 
the doses.
ADVERSE EFFECTS
The commonest adverse events 
reported in clinical trials were 
dose-related akathisia (ranging 
from 11–12 per cent at 40mg 
daily to 23–24 per cent at 120mg 
daily), headache, somnolence, 
nausea and parkinsonism.2,3,5 In 
one trial, lurasidone did not sig-
nificantly affect glycaemic con-
trol or lipid levels compared with 
placebo.4,6 
 A recent meta-analysis7 found 
that lurasidone treatment had 
no effects on weight gain or QTc 
interval prolongation compared 
to placebo in patients with schizo-
phrenia and was significantly less 
likely to cause these effects than 
risperidone, quetiapine and olan-
zapine. Lurasidone treatment was 
associated with increased rates 
of sedation compared to placebo 
(odds ratio 2.45), similar to many 
other antipsychotics, but was signif-
icantly better than chlorpromazine 
and clozapine. 
 Lurasidone treatment had a 
small effect in increasing prolactin 
levels, and was significantly worse 
than aripiprazole or quetiapine, 
which had placebo level effects on 
prolactin levels. 
 Importantly, lurasidone was 
found to be one of the least well-tol-
erated antipsychotics with regard 
to extrapyramidal side-effects 
(odds ratio compared to placebo 
2.45), and lurasidone treatment 
was associated with significantly 
higher rates of extrapyramidal 
side-effects than aripiprazole, que-
tiapine, olanzapine or clozapine. 
 Lurasidone is predominantly 
metabolised by hepatic CYP3A4 
enzymes. It should not be co-
administered with strong inhibi-
tors or inducers of CYP3A4 and 
the dose should be limited to 40mg 
daily with a moderate CYP3A4 
inhibitor such as diltiazem. No 
dose adjustment is required when 
lurasidone is taken with lithium.
POTENTIAL PLACE IN CLINICAL PRACTICE?
Lurasidone will offer a new treat-
ment option for patients with schiz-
ophrenia and bipolar I depression; 
however, its role in the treatment 
of manic episodes of bipolar I 
disorder has yet to be evaluated. 
Significant benefits have been 
demonstrated for treating psy-
chotic and depressive symptoms 
and lurasidone’s lack of effect on 
weight gain or QTc-interval pro-
longation seems favourable. 
 The main adverse effect of 
note appears to be increased rates 
of extrapyramidal side-effects and 
we would suggest that clinicians 
consider this when using lurasi-
done for patient populations 
who may be particularly likely to 
develop or who have previously not 
be able to tolerate these symptoms. 
 Overall, it seems likely that 
lurasidone will be carefully con-
sidered on its merits for inclusion 
into current treatment protocols 
for both schizophrenia and bipolar 
I depression.
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